Biotech News

Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria

Synlogic (SYBX)SynlogicCompany update

Findings support positive proof of mechanism, through successful degradation of methionine, precursor to homocysteine, using dietary disease model in preclinical models and healthy volunteer study SYNB1353 was well-tolerated, with similar proportions in both the placebo and active arms reporting

Open original release

Related news

SYBXSynlogic2024-02-08 21:15 EST

Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update

SYBXSynlogic2024-01-04 12:00 EST

Synlogic Provides Corporate Update and Outlook for 2024

MISTMilestone Pharmaceuticals Inc.2026-03-20 11:55 EST

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT

NAMSNewAmsterdam Pharma2026-07-24 12:00 EST

NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)

VANIVivani Medical2026-06-25 11:30 EST

Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management

ALGSAligos Therapeutics2026-05-13 06:05 EST

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

ALGSAligos Therapeutics2026-04-14 20:05 EST

Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation

MLYSMineralys Therapeutics2026-03-09 20:30 EST

Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results

Synlogic

Synlogic was a synthetic-biology company focused on engineered microbes and metabolic disease before its restructuring and decline. Its platform aimed to use living medicines to address rare disorders.

Recent company news

Stock data

Close
0.67 USD
Market cap
Exchange
NASDAQ
Sector
Biopharma
Location
United States